Currently, there are 174.10M common shares owned by the public and among those 157.78M shares have been available to trade.
The company’s stock has a 5-day price change of -16.67% and -38.11% over the past three months. AUTL shares are trading -40.99% year to date (YTD), with the 12-month market performance up to 119.65% higher. It has a 12-month low price of $1.64 and touched a high of $7.45 over the same period. AUTL has an average intraday trading volume of 1.68 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -23.54%, -32.55%, and -13.85% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Autolus Therapeutics plc ADR (NASDAQ: AUTL) shares accounts for 61.84% of the company’s 174.10M shares outstanding.
It has a market capitalization of $661.58M and a beta (3y monthly) value of 2.00. The earnings-per-share (ttm) stands at -$1.20. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.51% over the week and 6.87% over the month.
Analysts forecast that Autolus Therapeutics plc ADR (AUTL) will achieve an EPS of -$0.05 for the current quarter, -$0.2 for the next quarter and -$0.59 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.28 while analysts give the company a high EPS estimate of $0.42. Comparatively, EPS for the current quarter was -$0.23 a year ago. Earnings per share for the fiscal year are expected to increase by 42.57%, and 17.43% over the next financial year.
Looking at the support for the AUTL, a number of firms have released research notes about the stock. Deutsche Bank stated their Buy rating for the stock in a research note on November 09, 2023, with the firm’s price target at $10. Wells Fargo coverage for the Autolus Therapeutics plc ADR (AUTL) stock in a research note released on March 27, 2023 offered a Overweight rating with a price target of $8. Bryan Garnier was of a view on March 17, 2023 that the stock is Buy, while Jefferies gave the stock Buy rating on June 14, 2021, issuing a price target of $6- $12. JP Morgan on their part issued Neutral rating on January 29, 2021.
